AFT Pharmaceuticals hits $200m revenue milestone despite profit dip

AFT Pharmaceuticals hits $200m revenue milestone despite profit dip
AFT co-founder Dr Hartley Atkinson says launching into new markets takes time to reap rewards. (Image: AFT Pharmaceuticals)
Rebecca Stevenson
AFT Pharmaceuticals' co-founder, Dr Hartley Atkinson, says the firm’s choice to invest in Australia has been vindicated. The dual-listed pharmaceutical company released its results for the year ended March 31 on Thursday. While profit after tax fell to $11.9 million, revenue cracked $200m for the first time. Revenue from Australia increased by 17% to $127.1m, and operating profit leapt 65% to $25.5m. Chief executive Atkinson said AFT's investment in Australia had caused some concern, but the result proved its strate...

More Markets

Consumer confidence ticks up in June
Retail

Consumer confidence ticks up in June

The ANZ-Roy Morgan Consumer Confidence index lifted 6 points to 98.8 in June.The future conditions index – made up of forward-looking questions – rose 8 points to 104.8, recovering last month’s fall. The current conditions index rose 3 points to 89.8.Perceptions of current person...

Monthly CPI tech takes Stats NZ into the future
Economy

Monthly CPI tech takes Stats NZ into the future

Budget funding for new inflation-reporting tech is a giant leap forward, agency says.

Fonterra leads NZ sharemarket rise
Markets Market Close

Fonterra leads NZ sharemarket rise

The NZX 50 grew by 0.15% to 12,480.05 as Fonterra performed well.

Tom Raynel 26 Jun 2025
NZ sharemarket flat despite export growth
Markets Market close

NZ sharemarket flat despite export growth

The NZ sharemarket dipped as Fletcher Building shares fell further.

Tom Raynel 25 Jun 2025